Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred

Next Previous
Trial Profile

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Racemetyrosine (Primary) ; Capecitabine; Fluorouracil; Gemcitabine; Methoxsalen; Phenytoin; Sirolimus
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TYME-88-PANC
  • Sponsors Tyme Technologies

Most Recent Events

  • 26 Jan 2022 According to a Tyme Technologies media release, TYME announced the discontinuation of this trial upon learning that trial sponsor terminated the study arm due to futility. Notwithstanding the discontinuation of this clinical trial, the Company believes there are additional opportunities that could enhance value for TYME stockholders. it believe that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moeli
  • 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
  • 09 Dec 2021 According to a Tyme Technologies media release, final results from the study have been accepted for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top